ctDNA Monitoring in Early Breast Cancer
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorGeneplus-Beijing Co. Ltd.
About this trial
This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.
Eligibility criteria
Qualifiers
Patients aged 18 to 80 years old
Histologically proven primary breast cancer with clinical stage I-III
Patients with neoadjuvant therapy, and/or radical surgery/breast conserving surgery, adjuvant chemotherapy and target therapy (Her2+), radiotherapy (if indicated).
Expected to achieve R0 resection.
Disqualifiers
Patients intended to receive adjuvant chemotherapy with Eastern Cooperative Oncology Group (ECOG) performance status 3, 4 or 5.
Patients intended to receive postoperative radiotherapy with Eastern Cooperative Oncology Group (ECOG) performance status 5.
Prior diagnosis of cancer in the previous 5 years, other than for basal cell carcinoma of the skin or cervical carcinoma in situ.
Presence of any systemic illness incompatible with participation in the clinical trial or inability to provide written informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Geneplus-Beijing Co. Ltd.
Lead sponsor
Army Medical University, China
Collaborator
Source ClinicalTrials.gov